Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 26, 2024
Daily News
August 26, 2024
- Mitsubishi Walks Away from Collategene Deal with AnGes
August 26, 2024
- GSK Introduces Asthma Drug Relvar for Children in Japan
August 26, 2024
- A Time for Patience - 3: As iPSC-Based Drug Discovery Advances, Will 2 Existing Meds Be Repurposed for ALS?
August 26, 2024
- UK OKs Eisai’s Alzheimer’s Drug, but Health Coverage Nixed
August 26, 2024
- Moderna’s JN.1-Tailored COVID Vaccine Approved in Japan
August 26, 2024
- MHLW to Address Drug Loss, Generic Industry Reform in FY2025 Budget Request
August 26, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…